ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

NCT04561245 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and side effects of the experimental drug Pemvidutide (ALT-801) in healthy adults who are overweight or obese.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 100 people

Who can join Ages 18–60 · all sexes Healthy volunteers accepted.

Timeline Started 2020-11 · est. completion 2021-10

Where 1 site · Australia

What this study is testing ClinicalTrials.gov NCT04561245 ↗

Description as written by the study sponsor.

This study was a FIH, Phase 1, randomized, double-blind, placebo-controlled, 2-part single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ALT-801 (pemvidutide) in healthy overweight and obese subjects. The purpose of the study was to assess the safety and tolerability in healthy overweight and obese volunteers administered single or multiple repeated doses of ALT-801 (pemvidutide).

Treatments tested

ALT-801 also known as Pemvidutide Drug

Injected subcutaneously (SC)
Placebo Other

Injected subcutaneously (SC)

Main thing measured	The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)
Sponsor	Altimmune, Inc.
Conditions studied	Obesity, Nonalcoholic Steatohepatitis
GLP-1 drugs	pemvidutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04561245 ↗